← All trials
NCT05203315
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 17, 2022
- Primary completion
- Sep 1, 2022
- Completion date
- Dec 1, 2022
- First posted
- Jan 24, 2022
- Last posted
- Mar 22, 2022
- Enrollment
- 40
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Austin Institute for Clinical ResearchLead sponsor
- Austin Institute for Clinical ResearchOverall official - principal investigator
- Austin Institute for Clinical ResearchOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.